Abbott Laboratories (ABT.US) loses 1.50% in pre-market trading after releasing Q4 2024 results. Abbott has concluded 2024 on a high note, showcasing robust performance and delivering results that align with market expectations. The company remains positioned for substantial growth in 2025, driven by rising demand for its cutting-edge medical devices, particularly continuous glucose monitoring systems.
Key Financial Highlights (2024):
- Fourth-Quarter Performance:
- Reported sales of $11 billion, marking a 7.2% increase.
- Organic sales (excluding COVID-19 testing) grew by 10.1%.
- Adjusted diluted EPS: $1.34, in line with market estimates.
- Full-Year 2024 Performance:
- Total sales of $42 billion, reflecting a 4.6% increase on a reported basis.
- Organic sales (excluding COVID-19 testing) climbed by 9.6%.
- GAAP diluted EPS: $7.64; Adjusted diluted EPS: $4.67.
- Gross margin improved by 70 basis points on an adjusted basis.
- Achieved the upper range of its initial guidance for both sales growth and adjusted EPS.
- Medical Devices:
- Full-year sales reached $19 billion, a $2 billion increase YoY.
- Flagship products such as FreeStyle Libre, Navitor, and Amplatzer Amulet drove double-digit growth, with FreeStyle Libre sales soaring 22.7% YoY.
Guidance for 2025:
Abbott projects another year of strong growth across its business segments:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app- Organic Sales Growth: 7.5%–8.5%.
- Adjusted Operating Margin: 23.5%–24.0% (150 basis points increase YoY).
- Adjusted Diluted EPS: $5.05–$5.25 (midpoint reflects double-digit growth).
The company's innovation pipeline remains a key driver of future performance, with over 15 new growth initiatives announced in 2024, including new product launches and expanded treatment indications.
Strategic and Operational Highlights:
- Dividends: Abbott declared its 404th consecutive quarterly dividend, reflecting a 53-year streak of annual increases. The dividend payout stands at $0.59 per share, positioning Abbott as a member of the S&P 500 Dividend Aristocrats Index.
- Market Tailwinds: Increased awareness of diabetes care, broader insurance coverage, and patient preference for non-invasive devices like FreeStyle Libre are bolstering demand.
- Strong R&D Productivity: The company continues to prioritize innovation, leveraging its diverse healthcare portfolio to meet rising global demand.
CEO Commentary:
"We closed the year with strong momentum, achieving the highest sales and EPS growth of 2024 in the fourth quarter," said Robert B. Ford, Chairman and CEO. "Our track record of delivering on commitments positions us for another strong year in 2025."
Forward-Looking Considerations:
Abbott’s focus on core business growth, disciplined cost management, and a pipeline of innovative products align with its vision of long-term shareholder value creation. While the company has not disclosed specific GAAP financial measures for 2025, it remains committed to delivering sustainable growth through strategic investments and operational excellence.

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.